Esophageal Cancer - Pipeline Review, H1 2018

  • ID: 4482729
  • Drug Pipelines
  • 639 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ADC Therapeutics Sarl
  • Boehringer Ingelheim GmbH
  • Genmab A/S
  • Incyte Corp
  • Moderna Therapeutics Inc
  • Soricimed Biopharma Inc
  • MORE
Esophageal Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H1 2018, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 8, 44, 34, 3 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 3 and 1 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ADC Therapeutics Sarl
  • Boehringer Ingelheim GmbH
  • Genmab A/S
  • Incyte Corp
  • Moderna Therapeutics Inc
  • Soricimed Biopharma Inc
  • MORE
Introduction

Esophageal Cancer - Overview

Esophageal Cancer - Therapeutics Development

Esophageal Cancer - Therapeutics Assessment

Esophageal Cancer - Companies Involved in Therapeutics Development

Esophageal Cancer - Drug Profiles

Esophageal Cancer - Dormant Projects

Esophageal Cancer - Discontinued Products

Esophageal Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Esophageal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Esophageal Cancer - Pipeline by ADC Therapeutics Sarl, H1 2018

Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Esophageal Cancer - Pipeline by Almac Discovery Ltd, H1 2018

Esophageal Cancer - Pipeline by Ambrx Inc, H1 2018

Esophageal Cancer - Pipeline by Amgen Inc, H1 2018

Esophageal Cancer - Pipeline by Aprea AB, H1 2018

Esophageal Cancer - Pipeline by ArQule Inc, H1 2018

Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Esophageal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by Bayer AG, H1 2018

Esophageal Cancer - Pipeline by BeiGene Ltd, H1 2018

Esophageal Cancer - Pipeline by BioStar Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Esophageal Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Esophageal Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2018

Esophageal Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by Celgene Corp, H1 2018

Esophageal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018

Esophageal Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Esophageal Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H1 2018

Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Eisai Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Eli Lilly and Co, H1 2018

Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Esophageal Cancer - Pipeline by Genmab A/S, H1 2018

Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2018

Esophageal Cancer - Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Hutchison MediPharma Ltd, H1 2018

Esophageal Cancer - Pipeline by Idera Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by Ignyta Inc, H1 2018

Esophageal Cancer - Pipeline by Immunocore Ltd, H1 2018

Esophageal Cancer - Pipeline by ImmunoFrontier Inc, H1 2018

Esophageal Cancer - Pipeline by Immunomedics Inc, H1 2018

Esophageal Cancer - Pipeline by Incyte Corp, H1 2018

Esophageal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Johnson & Johnson, H1 2018

Esophageal Cancer - Pipeline by Leap Therapeutics Inc, H1 2018

Esophageal Cancer - Pipeline by Lycera Corp, H1 2018

Esophageal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H1 2018

Esophageal Cancer - Pipeline by MaxCyte Inc, H1 2018

Esophageal Cancer - Pipeline by MaxiVAX SA, H1 2018

Esophageal Cancer - Pipeline by Mebiopharm Co Ltd, H1 2018

Esophageal Cancer - Pipeline by MedImmune LLC, H1 2018

Esophageal Cancer - Pipeline by Merck & Co Inc, H1 2018

Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by Moderna Therapeutics Inc, H1 2018

Esophageal Cancer - Pipeline by Novartis AG, H1 2018

Esophageal Cancer - Pipeline by Omeros Corp, H1 2018

Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2018

Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H1 2018

Esophageal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Puma Biotechnology Inc, H1 2018

Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals SA, H1 2018

Esophageal Cancer - Pipeline by Shionogi & Co Ltd, H1 2018

Esophageal Cancer - Pipeline by Soricimed Biopharma Inc, H1 2018

Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018

Esophageal Cancer - Pipeline by Steba Biotech SA, H1 2018

Esophageal Cancer - Pipeline by Stelic Institute & Co Inc, H1 2018

Esophageal Cancer - Pipeline by Supratek Pharma Inc, H1 2018

List of Figures

Number of Products under Development for Esophageal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics Sarl
  • Advenchen Laboratories LLC
  • Almac Discovery Ltd
  • Ambrx Inc
  • Amgen Inc
  • Aprea AB
  • ArQule Inc
  • Aslan Pharmaceuticals Pte Ltd
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • BioStar Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cascadian Therapeutics Inc
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chugai Pharmaceutical Co Ltd
  • CSPC Pharmaceutical Group Limited
  • Cyclacel Pharmaceuticals Inc
  • DAE HWA Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Glycotope GmbH
  • Guangzhou Saliai Stemcell Science and Technology Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hutchison MediPharma Ltd
  • Idera Pharmaceuticals Inc
  • Ignyta Inc
  • Immunocore Ltd
  • ImmunoFrontier Inc
  • Immunomedics Inc
  • Incyte Corp
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Leap Therapeutics Inc
  • Lycera Corp
  • Madrigal Pharmaceuticals Inc.
  • MaxCyte Inc
  • MaxiVAX SA
  • Mebiopharm Co Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • Moderna Therapeutics Inc
  • Novartis AG
  • Omeros Corp
  • Omnitura Therapeutics Inc
  • Oncolys BioPharma Inc
  • Ono Pharmaceutical Co Ltd
  • Puma Biotechnology Inc
  • Rhizen Pharmaceuticals SA
  • Shionogi & Co Ltd
  • Soricimed Biopharma Inc
  • Spectrum Pharmaceuticals Inc
  • Steba Biotech SA
  • Stelic Institute & Co Inc
  • Supratek Pharma Inc
  • Symphogen A/S
  • Taiho Pharmaceutical Co Ltd
  • Takara Bio Inc
  • Transgene Biotek Ltd
  • Transgene SA
  • Tyg Oncology Ltd
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll